Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Seglor
- Development stage
- Unknown
- Lead developer
- Acarpia Farmaceutici
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Seglor is a modified-release hard capsule containing dihydroergotamine mesylate (5 mg) as the active ingredient, developed and marketed by Acarpia Farmaceutici. It is indicated for the treatment of migraine, headaches, and vertigo. Dihydroergotamine is a hydrogenated derivative of ergotamine and belongs to the anti-migraine (antiemicranicis) class of medications. It acts as a non-selective agonist at serotonin receptors, particularly the 5-HT1B, 5-HT1D, and 5-HT1F subtypes. This agonism leads to the vasoconstriction of dilated intracranial blood vessels and inhibits the release of pro-inflammatory neuropeptides from trigeminal nerve endings, thereby alleviating headache symptoms. Dihydroergotamine also exhibits activity at alpha-adrenergic and dopamine receptors. The modified-release formulation of Seglor is designed to provide sustained therapeutic effects and is approved for use in Italy.
- Brand names
- Seglor
- Other names
- dihydroergotamine mesylate
02
Targets
ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1F (Serotonin 5-HT1F receptor)HTR1D (5-hydroxytryptamine receptor 1D)ADRA2A (α2A)
Beyond the preview
Go deeper on Seglor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Seglor.